Introduction

Narcotic Concealment Methods in U.S. Customs and Border Protection and the Emergence of Counterfeit Tablets Containing Fentanyl in the United States

Narcotic Concealment Methods in U.S. Customs and Border Protection and the Emergence of Counterfeit Tablets Containing Fentanyl in the United States

← Back to Unseen Threats Webinar Series

This webinar originally occurred on May 26, 2022
Duration: 1 hour

Overview

With nearly 6,000 miles of border to patrol and screening passengers and cargo at over 130 airports, seaports, and land border crossings, U.S. Customs and Border Protection (CBP) plays a vital role in the interception of narcotics and other illicit goods that are entering the country. With constantly changing drug trends, varying supply routes, and a wide variety of concealment methods, Customs Officers and Border Patrol Agents intercepting narcotics coming into the country is never a straightforward endeavor. Fortunately, advanced intel gathering and sharing allow new concealment strategies to be shared with CBP employees as well as other federal, state, and local law enforcement agencies. Our first presenter will provide an overview of some of the more unique concealment methods utilized by drug traffickers, as well as some of the sampling and extraction methods used to prepare these submissions for analyses.

In recent years, counterfeit tablets containing fentanyl have become a persistent component of the illicit drug market in the United States. Foreign and domestic preparation of these tablets often occurs in austere conditions leading to inconsistent composition. This, along with the fact that these tablets often bear the markings of legitimate pharmaceutical products, makes these counterfeit tablets an unassuming but serious threat to law enforcement and end users alike. Our second presenter will discuss trends associated with counterfeit tablets containing fentanyl seized by the U.S. Drug Enforcement Administration.

Detailed Learning Objectives

  1. Attendees will receive an overview of instrumentation used by officers to detect large scale concealments.
  2. Attendees will learn about large and small-scale drug concealments that have been submitted to the lab for analysis.
  3. Attendees will understand trends associated with counterfeit tablets containing fentanyl in the United States and recognize the threats associated with fentanyl in this form.

Presenters

  • Jason Bory, M.S. | Assistant Director, New York Laboratory, U.S. Customs and Border Protection
  • Emily Lockhart, M.S. | Senior Forensic Chemist, Special Testing and Research Laboratory, U.S. Drug Enforcement Administration

Funding for this Forensic Technology Center of Excellence webinar has been provided by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice.

The opinions, findings, and conclusions or recommendations expressed in this webinar are those of the presenter(s) and do not necessarily reflect those of the U.S. Department of Justice.

Contact us at ForensicCOE@rti.org with any questions and subscribe to our newsletter for notifications.


Related Content

White Paper – Forensic Community Drug Database Conceptualization

Date February 2024 Overview The National Institute of Justice (NIJ)-in partnership with its Forensic Technology Center of Excellence (FTCOE) at RTI International and the National Center for Health Statistics, Centers for Disease Control and Prevention (CDC)-convened a virtual Medicolegal Death…

Technical Note – The Use of Neutral Losses and Common Fragments Screening by QTOF in Forensic Laboratories

Date February 2024 Overview Quadrupole time-of-flight (QTOF) mass spectrometry is an advanced analytical technique that has some capabilities that make it particularly useful in screening in toxicology cases for unknown analytes. The technology combines the power of a quadrupole mass…

Drug Surveillance Initiatives: An FTCOE Repository of Resources

Date December 2023 Overview In the realm of drug surveillance, a multitude of data sources originate from diverse funding agencies, including but not limited to the Drug Enforcement Administration (DEA), National Institute on Drug Abuse (NIDA), Centers for Disease Control…